Université de Strasbourg, Centre Régional de Lutte contre le Cancer Paul Strauss, Laboratoire de Radiobiologie EA-3430, 3 rue de la Porte de l'Hôpital, F-67065 Strasbourg, France.
Expert Opin Ther Pat. 2010 Jan;20(1):73-101. doi: 10.1517/13543770903490429.
Ionizing radiation (IR) can produce deleterious effects in living tissues, leading to significant morbidity and a potentially fatal illness affecting various organs dose-dependently. As people may be exposed to IR during cancer radiotherapy or as a result of a radiological/nuclear incident or act of terrorism, the danger of irradiation represents a serious public health problem. At present, however, this problem remains largely impervious to medical management. There is, therefore, a pressing need to develop safe and effective radiation countermeasure (RC) agents to prevent, mitigate or treat the harmful consequences of IR exposure.
Recent advances in the search for RC agents as reflected by the relevant patent literature of the past five years along with peer-reviewed publications are surveyed.
A total of 43 patents, describing approximately 38 chemically diverse compounds with RC potential are analyzed. These include antioxidants capable of scavenging IR-induced free radicals, modulators of cell death signaling or cell cycle progression, cytokines or growth factors promoting tissue repair and inhibitors of inflammatory cytokines.
Several of these RC candidates appear promising, including at least two that are undergoing evaluation for fast-track clinical development.
电离辐射（IR）会对活组织产生有害影响，导致发病率显著增加，并可能导致各种器官潜在致命的疾病，其严重程度与剂量呈依赖关系。由于人们可能在癌症放射治疗过程中或由于放射性/核事故或恐怖主义行为而暴露于 IR 下，照射的危险是一个严重的公共卫生问题。然而，目前，这个问题在很大程度上仍然无法通过医学管理来解决。因此，迫切需要开发安全有效的辐射对策（RC）剂，以预防、减轻或治疗 IR 暴露的有害后果。
通过过去五年的相关专利文献和同行评议出版物，调查了 RC 剂研究的最新进展。
共分析了 43 项专利，描述了大约 38 种具有 RC 潜力的化学多样性化合物。这些包括能够清除 IR 诱导自由基的抗氧化剂、细胞死亡信号或细胞周期进展的调节剂、促进组织修复的细胞因子或生长因子以及炎症细胞因子抑制剂。
这些 RC 候选药物中有几种似乎很有前途，其中至少有两种正在进行快速临床开发的评估。
